Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
Regeneron(REGN) stock is priced at $751.35, giving the company a market capitalization of 78.97B. It carries a P/E multiple of 17.94 and pays a dividend yield of 47.0%.
On 2026-01-30, Regeneron(REGN) stock moved within a range of $728.00 to $774.37. With shares now at $751.35, the stock is trading +3.2% above its intraday low and -3.0% below the session's peak.
Trading activity shows a volume of 554.1K, compared to an average daily volume of 894.68K.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
The stock's 52-week range extends from a low of $476.49 to a high of $821.11.
REGN News
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported fourth-quarter adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consen...
Image source: The Motley Fool. Jan. 30, 2026, 8:30 a.m. ET Call participants President and Chief Executive Officer — Dr. Leonard Schleifer Board Co-Chair, Pres...
Regeneron stock slipped early Friday after the biotech behemoth reported adjusted earnings of $11.44 per share on $3.88 billion in fourth-quarter sales. Analyst...
Analyst ratings
70%
of 30 ratingsMore REGN News
Reports Q4 revenue $3.9B, consensus $3.79B. “Regeneron (REGN) performed well in 2025, with financial strength driven by our four blockbuster medicines and futur...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for its fourth quarter, before the opening bell on Friday, Jan. 30. Analysts expect...
TD Cowen raised the firm’s price target on Regeneron (REGN) to $820 from $800 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 resul...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.